top of page

Representative publications:

  1. Huang W#, Cao M#, Wu Y#, Zhang Y, An S, Pan X, Zhou X, Shao H, Guan Y, Huang G, Gelardi F, Chiti A, Xie F*, Liu J*, Wei W*. Immuno-PET/CT Imaging of Trop2 with [18F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation. J Nucl Med. 2024 Dec 3;65(12):1904-1910. doi: 10.2967/jnumed.124.268751. PMID: 39542697.

  2. Zhou X#, Wu Q#, Zhai W#, Zhang Y, Wu Y, Cao M, Wang C, Guan Y, Liu J*, Xie F*, Wei W*. CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study. J Nucl Med. 2024 Dec 3;65(12):1891-1898. doi: 10.2967/jnumed.124.268509. PMID: 39510586.

  3. An S#, Wang L, Xie F, Jiang D, Huang G, Liu J, Ma X, Wei W*. Pathway to Approval of Innovative Radiopharmaceuticals in China. J Nucl Med. 2024 May 6;65(Suppl 1):72S-76S. doi: 10.2967/jnumed.123.267127. PMID: 38719236.

  4. Zhang Y#, Cao M#, Wu Y#, Malih S, Xu D, Yang E, Younis MH, Lin W, Zhao H, Wang C, Liu Q, Engle JW, Rasaee MJ, Guan Y, Huang G, Liu J, Cai W*, Xie F*, Wei W*. Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers. Journal for ImmunoTherapy of Cancer 2024;12:e008794. doi: 10.1136/jitc-2024-008794.

  5. Huang W#, Zhang Y#, Cao M#, Wu Y, Jiao F, Chu Z, Zhou X, Li L, Xu D, Pan X, Guan Y, Huang G, Liu J*, Xie F*, Wei W*. ImmunoPET imaging of Trop2 in patients with solid tumours. EMBO Mol Med. 2024 Apr 2. 1-19-19. PMID: 3856580

  6. Qianyun Wu#, Yanfei Wu#, You Zhang#, Yihui Guan, Gang Huang, Fang Xie, Jianjun Liu*, Wei Zhai* & Weijun Wei*. ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study. Eur J Nucl Med Mol Imaging (2024).1619-7089.https://doi.org/10.1007/s00259-024-06672-3

  7. Cheng Wang#, Yumei Chen#, Yun Nan Hou, Qiufang Liu , Di Zhang , Haitao Zhao , You Zhang , Shuxian An, Lianghua Li, Jian Hou , Gang Huang, Jianjun Liu*, Yong Juan Zhao*, Weijun Wei*. ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053. European Journal of Nuclear Medicine and Molecular Imaging. 2021 Aug;48(9):2749-2760.

  8. Wei W#, Jiang D#, Lee HJ, Li M, Kutyreff CJ, Engle JW, Liu J*, Cai W*. Development and characterization of CD54-targeted immunoPET imaging in solid tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(12):2765-2775.

  9. Wei W#, Liu Q#, Jiang D, Zhao H, Kutyreff CJ, Engle JW, Liu J*, Cai W*. Tissue Factor-Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer. Advanced Science. 2020;7(13):1903595.

  10. Wei W#, Jiang D#, Ehlerding EB, Barnhart TE, Yang Y, Engle JW, Luo QY*, Huang P*, Cai W*. CD146-Targeted Multimodal Image-Guided Photoimmunotherapy of Melanoma. Advanced Science. 2019;6(9):1801237.

  11. Wei W, Rosenkrans ZT, Liu J, Huang G*, Luo Q-Y*, Cai W*. ImmunoPET: Concept, Design, and Applications. Chemical Reviews. 2020;120(8):3787-3851.

  12. Shuxian An, Di Zhang , You Zhang, Cheng Wang, Liang Shi, Weijun Wei, Gang Huang, Jianjun Liu. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. European Journal of Nuclear Medicine and Molecular Imaging. 2022 Jul;49(8):2682-2692.

  13. Wei W*,#, Zhang D#, Wang C, Zhang Y, An S, Chen Y, Huang G, Liu J*. Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053. Mol Pharm. 2022 Oct 3;19(10):3502-3510. doi: 10.1021/acs.molpharmaceut.1c00733. Epub 2021 Nov 30. PMID: 34846151.

  14. Wei W*,#, Zhang Y#, Zhang D, Liu Q, An S, Chen Y, Huang G, Liu J*. Annotating BCMA Expression in Multiple Myelomas. Mol Pharm. 2022 Oct 3;19(10):3492-3501. doi: 10.1021/acs.molpharmaceut.1c00628. Epub 2021 Nov 29. PMID: 34843261.

  15. Wei W, Younis MH, Lan X, Liu J, Cai W. Single-Domain Antibody Theranostics on the Horizon. J Nucl Med. 2022 Oct;63(10):1475-1479.

​

Publication list:

  1. Shi B, Zhang Y, Wu S, et al. CD70-Targeted [18F]RCCB6 Immuno-PET/CT Imaging in Patients with Nasopharyngeal Carcinoma: A Proof-of-Concept Study. J Nucl Med. Published online April 30, 2025. doi:10.2967/jnumed.125.269585

  2. Wei W, Grünwald V, Herrmann K. CD70-targeted cancer theranostics: Progress and challenges. Med. Published online April 11, 2025. doi:10.1016/j.medj.2025.100671

  3. Wu Q, Shao H, Zhai W, et al. Molecular imaging of renal cell carcinomas: ready for prime time. Nat Rev Urol. Published online November 14, 2024. doi:10.1038/s41585-024-00962-z

  4. Wu S, Wu Q, Liu J, Zhang J, Wei W. [18F]RCCB6 immunoPET/CT detects primary clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. Published online December 7, 2024. doi:10.1007/s00259-024-07001-4

  5. Xu D, Zhang Y, Huang W, Pan X, An S, Wang C, Huang G, Liu J, Wei W. ImmunoPET imaging of EpCAM in solid tumours with nanobody tracers: a preclinical study. Eur J Nucl Med Mol Imaging. 2024 Sep 9. doi: 10.1007/s00259-024-06910-8.

  6. Zhou X, Shi B, Huang G, Liu J, Wei W. Trends in cancer imaging. Trends Cancer. Published online September 3, 2024. doi:10.1016/j.trecan.2024.08.006

  7. Wu Q, Wu Y, Zhang Y, et al. [18F]RCCB6 Immuno-Positron Emission Tomography/Computed Tomography for Postoperative Surveillance in Clear Cell Renal Cell Carcinoma: A Pilot Clinical Study. Eur Urol. Published online July 22, 2024. doi:10.1016/j.eururo.2024.06.020

  8. An S, Wang L, Xie F, Jiang D, Huang G, Liu J, Ma X, Wei W. Pathway to Approval of Innovative Radiopharmaceuticals in China. J Nucl Med. 2024 May 6;65(Suppl 1):72S-76S. doi: 10.2967/jnumed.123.267127. PMID: 38719236.

  9. Zhang Y, Cao M, Wu Y, et al. Preclinical development of novel PD-L1 tracers and first-in-human study of [68Ga]Ga-NOTA-RW102 in patients with lung cancers. Journal for ImmunoTherapy of Cancer 2024;12:e008794. doi: 10.1136/jitc-2024-008794.

  10. Huang W, Zhang Y, Cao M, Wu Y, Jiao F, Chu Z, Zhou X, Li L, Xu D, Pan X, Guan Y, Huang G, Liu J, Xie F, Wei W. ImmunoPET imaging of Trop2 in patients with solid tumours. EMBO Mol Med. 2024 Apr 2. 1-19-19. PMID: 38565806.

  11. Qianyun Wu#, Yanfei Wu#, You Zhang#, Yihui Guan, Gang Huang, Fang Xie, Jianjun Liu*, Wei Zhai* & Weijun Wei*. ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F]RCCB6: a first-in-human study. Eur J Nucl Med Mol Imaging (2024).1619-7089.https://doi.org/10.1007/s00259-024-06672-3

  12. Huang W, Liang C, Zhang Y, Zhang D, An S, Wu Q, Li J, Zhao H, Wang C, Cui J, Bao Z, Huang G, Wei W, Liu J. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers. Eur J Nucl Med Mol Imaging. 2024 Jan;51(2):380-394. doi: 10.1007/s00259-023-06454-3. Epub 2023 Oct 4. PMID: 37792026.

  13. Zhou S, Fang X, Lv J, Yang Y, Zeng Y, Liu Y, Wei W, Huang G, Zhang B, Wu C. Site-Specific Modification of Single Domain Antibodies by Enzyme-Immobilized Magnetic Beads. Bioconjug Chem. 2023 Oct 18;34(10):1914-1922. doi: 10.1021/acs.bioconjchem.3c00423. Epub 2023 Oct 7. PMID: 37804224.

  14. Liang, C., Huang, W., Zhang, Y., Zhang, D., An, S., Wu, Q., Zhao, H., Wang, C., Huang, G., Wei, W., & Liu, J. (2023). ImmunoPET Imaging of CD47 with VHH-Derived Tracers in Pancreatic Cancers. Molecular pharmaceutics, 20(8), 4184–4195. 

  15. Zhang D, Huang G, Liu J, Wei W*. Claudin18.2-targeted cancer theranostics. Am J Nucl Med Mol Imaging. 2023 Apr 25;13(2):64-69.

  16. Zhang Y, Zhang D, An S, Liu Q, Liang C, Li J, Liu P, Wu C, Huang G*, Wei W*, Liu J*. Development and Characterization of Nanobody-Derived CD47 Theranostic Pairs in Solid Tumors. Research (Wash D C). 2023;6:0077.

  17. Wu Q, Yang S, Liu J, Jiang D, Wei W*. Antibody theranostics in precision medicine. Med. 2023 Feb 10;4(2):69-74.

  18. Wei W*, Jiang D, Evangelista L, Cai W. Antibody-Based Imaging and Therapy for Precision Medicine. Mol Pharm. 2022 Oct 3;19(10):3453-3455.

  19. Wei W*. Voices in Molecular Pharmaceutics: Meet Dr. Weijun Wei Who Is Developing Theranostic Nuclear Medicine Agents for Clinical Use. Mol Pharm. 2022 Oct 3;19(10):3456.

  20. Xie F, Wei W*. [64Cu]Cu-ATSM: an emerging theranostic agent for cancer and neuroinflammation. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):3964-3972.

  21. An S, Huang G, Liu J, Wei W*. PSMA-targeted theranostics of solid tumors: applications beyond prostate cancers. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):3973-3976.

  22. Wei W, Younis MH, Lan X, Liu J, Cai W. Single-Domain Antibody Theranostics on the Horizon. J Nucl Med. 2022 Oct;63(10):1475-1479.

  23. Wang Q, Zhang X, Wei W*, Cao M*. PET Imaging of Lung Cancers in Precision Medicine: Current Landscape and Future Perspective. Mol Pharm. 2022 Oct 3;19(10):3471-3483.

  24. Wu Q, Huang G, Wei W*, Liu J*. Molecular Imaging of Renal Cell Carcinoma in Precision Medicine. Mol Pharm. 2022 Oct 3;19(10):3457-3470.

  25. Yang E, Liu Q, Huang G, Liu J, Wei W*. Engineering nanobodies for next-generation molecular imaging. Drug Discov Today. 2022 Jun;27(6):1622-1638.

  26. An S, Zhang D, Zhang Y, Wang C, Shi L, Wei W*, Huang G*, Liu J*. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2682-2692.

  27. Wei W, Zhang D, Wang C, Zhang Y, An S, Chen Y, Huang G, Liu J. Annotating CD38 Expression in Multiple Myeloma with [18F]F-Nb1053. Mol Pharm. 2022 Oct 3;19(10):3502-3510.

  28. Wei W, Zhang Y, Zhang D, Liu Q, An S, Chen Y, Huang G, Liu J. Annotating BCMA Expression in Multiple Myelomas. Mol Pharm. 2022 Oct 3;19(10):3492-3501.

  29. Dun Y, Huang G, Liu J, Wei W. ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality. Drug Discov Today. 2022 Apr;27(4):1196-1203.

  30. Wei W, Chen Y, Zhao X, Liu J. Myofibrosarcoma infiltrating pulmonary arteries diagnosed on 18F-FDG PET/CT. Cao M. Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1429-1430.

  31. Wei W*, Huang G, Liu J. Advancing the diagnosis of epithelioid hemangioendothelioma by 18F-FDG PET/CT. Am J Nucl Med Mol Imaging. 2021 Jun 15;11(3):230-232.

  32. Jin Y#, Liu B#, Younis MH, Huang G, Liu J, Cai W*, Wei W*. Next-Generation Molecular Imaging of Thyroid Cancer. Cancers (Basel). 2021 Jun 25;13(13):3188.

  33. Cheng Wang#, Yumei Chen#, Yun Nan Hou, Qiufang Liu , Di Zhang , Haitao Zhao , You Zhang , Shuxian An, Lianghua Li, Jian Hou , Gang Huang, Jianjun Liu*, Yong Juan Zhao*, Weijun Wei*. ImmunoPET imaging of multiple myeloma with [68Ga]Ga-NOTA-Nb1053. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2749-2760.

  34. Wei W#, Jiang D#, Lee HJ, Li M, Kutyreff CJ, Engle JW, Liu J*, Cai W*. Development and characterization of CD54-targeted immunoPET imaging in solid tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(12):2765-2775.

  35. Wei W#, Liu Q#, Jiang D, Zhao H, Kutyreff CJ, Engle JW, Liu J*, Cai W*. Tissue Factor-Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer. Advanced Science. 2020;7(13):1903595.

  36. Wei W, Rosenkrans ZT, Liu J, Huang G*, Luo Q-Y*, Cai W*. ImmunoPET: Concept, Design, and Applications. Chemical Reviews. 2020;120(8):3787-3851. (IF= 52.758)

  37. Weijun Wei, Dawei Jiang , Hye Jin Lee , Jonathan W Engle , Hisaya Akiba , Jianjun Liu , Weibo Cai. ImmunoPET Imaging of TIM-3 in Murine Melanoma Models. Adv Ther (Weinh). 2020 Jul;3(7):2000018.

  38. Miao Li#, Weijun Wei#, Todd E Barnhart, Dawei Jiang, Tianye Cao, Kevin Fan, Jonathan W Engle, Jianjun Liu, Weiyu Chen, Weibo Cai. ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2737-2748.

  39. Wei W#, Jiang D#, Ehlerding EB, Barnhart TE, Yang Y, Engle JW, Luo QY*, Huang P*, Cai W*. CD146-Targeted Multimodal Image-Guided Photoimmunotherapy of Melanoma. Advanced Science. 2019;6(9):1801237.

  40. Wei W, Jiang D, Rosenkrans ZT, Barnhart TE, Engle JW, Luo Q, Cai W. HER2-targeted multimodal imaging of anaplastic thyroid cancer. American Journal of Cancer Research. 2019;9(11):2413-2427.

  41. Wei W, Hardin H, Luo QY. Targeting Autophagy in Thyroid Cancers. Endocr Relat Cancer. 2019;26(4):R181-R194.

  42. Wei WJ#, Sun ZK#, Shen CT, Song HJ, Zhang XY, Qiu ZL*, Luo QY*. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer. Theranostics. 2017; 7(4):987-1001.

  43. Wei W#, Ehlerding EB#, Lan X*, Luo Q*, Cai W*. PET and SPECT imaging of melanoma: the state of the art. Eur J Nucl Med Mol Imaging. 2018; 45(1):132-150.

  44. Wei W#, Ehlerding EB#, Lan X*, Luo Q*, Cai W*. Molecular imaging of β-cells: diabetes and beyond. Adv. Drug Delivery Rev. 2019;139:16-31.

  45. Wei WJ*, Zhang GQ*, Luo QY. Postsurgical Management of Differentiated Thyroid Cancer in China. Trends Endocrinol Metab. 2018;29(2):71-73.

  46. Wei W#, Jiang D#, Ehlerding EB, Luo Q*, Cai W*. Noninvasive PET Imaging of T cells. Trends in Cancer. 2018. 4(5):359-373.

  47. Wei W#, Ni D#, Ehlerding EB, Luo QY*, Cai W*. PET imaging of receptor tyrosine kinases in cancer. Mol Cancer Ther. 2018;17(8):1625-1636.

  48. Wei W, Rosenkrans ZT, Luo QY#, Lan X#, Cai W#. Exploiting Nanomaterial-mediated Autophagy for Cancer Therapy. Small Methods. 2018, 1800365. DOI: 10.1002/smtd.201800365.

  49. Wei WJ#, Shen CT#, Song HJ, Qiu ZL*, Luo QY*. Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib. Oncol. Rep. 2016; 36 (3):1576-84.（IF=2.976）

  50. Wei WJ#, Shen CT#, Song HJ, Qiu ZL*, Luo QY*. MicroRNAs as a potential tool in the differential diagnosis of thyroid cancer: a systematic review and meta-analysis. Clin Endocrinol. 2016; 84(1):127-33.

  51. Wei WJ, Shen CT, Song HJ, Qiu ZL, Luo QY*. Metastatic malignant fibrous histiocytoma infiltrating sigmoid colon: A Case diagnosed with the help of 18F-FDG PET/CT. Clin Nucl Med. 2016; 41(4):338-40.

  52. Wei WJ, Sun ZK, Shen CT, Qiu ZL, Luo QY*. Adefovir-Induced Hypophosphatemic Osteomalacia Mimicking Bone Metastases From Primary Hepatocarcinoma. Clin Nucl Med. 2017; 42(9):e405-e406.

  53. Wei WJ#, Shen CT#, Song HJ, Qiu ZL*, Luo QY*. Comparison of SPET/CT, SPET and planar imaging using 99mTc-MIBI as independent techniques to support minimally invasive parathyroidectomy in primary hyperparathyroidism: A meta-analysis. Hell J Nucl Med. 2015; 18 (2):127-35.

  54. Wei WJ*, Sun ZK*, Shen CT, Zhang XY, Tang J, Song HJ, Qiu ZL, Luo QY. Value of 99mTc-MDP SPECT/CT and 18F-FDG PET/CT scanning in the evaluation of malignantly transformed fibrous dysplasia. Am J Nucl Med Mol Imaging. 2017; 7(3):92-104. ESCI

  55. Zhang GQ#, Wei WJ#, Song HJ, Sun ZK, Shen CT, Zhang XY, Chen XY, Qiu ZL*, Luo QY*. Programmed cell death-ligand 1 overexpression in thyroid cancer. Accepted. Endocrine Practice. 2019;25(3):279-286.

  56. Shen CT#, Wei WJ#, Song HJ, Qiu ZL, Luo QY*. Value of post-therapeutic 131I scintigraphy in stimulated serum thyroglobulin-negative patients with metastatic differentiated thyroid carcinoma. Endocrine. 2016; 51 (2): 283-90.

  57. Shen CT#, Wei WJ#, Song HJ, Qiu ZL, Luo QY*. Afamin promotes glucose metabolism in papillary thyroid carcinoma. Mol Cell Endocrinol. 2016; 434: 108-15.

  58. Shen CT#, Wei WJ#, Qiu ZL, Song HJ, Zhang XY, Sun ZK, Luo QY*. Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo. J Mol Endocrinol. 2017; 58 (1):15-23.

  59. Qiu ZL#, Wei WJ#, Sun ZK, Shen CT, Song HJ, Zhang XY, Zhang GQ, Chen XY, Luo QY*. Circulating Tumor Cells Correlate with Clinicopathological Features and Outcomes in Differentiated Thyroid Cancer. Cell Physiol Biochem. 2018; 48(2):718-730.

  60. Qiu ZL#, Wei WJ#, Shen CT, Song HJ, Zhang XY, Sun ZK, Luo QY*. Diagnostic Performance of 18F-FDG PET/CT in Papillary Thyroid Carcinoma with Negative 131I-WBS at first Postablation, Negative Tg and Progressively Increased TgAb Level. Sci Rep. 2017; 7(1):2849.

  61. Hye Jin Lee, Emily B Ehlerding , Dawei Jiang, Todd E Barnhart, Tianye Cao, Weijun Wei, Carolina A Ferreira, Peng Huang, Jonathan W Engle, Weibo Cai. Dual-labeled Pertuzumab for Multimodality Image-Guided Ovarian Tumor Resection. Am J Cancer Res, 9 (7), 1454-1468.

  62. Ni D, Ferreira CA, Barnhart TE, Quach V, Yu B, Jiang D, Wei W, Liu H, Engle JW, Hu P, Cai W. Magnetic Targeting of Nanotheranostics Enhances Cerenkov Radiation-Induced Photodynamic Therapy. J Am Chem Soc. 2018. 7; 140(44):14971-14979.

  63. Qiu ZL, Shen CT, Sun ZK, Wei WJ, Zhang XY, Song HJ, Luo QY. Circulating Long Non-Coding RNAs Act as Biomarkers for Predicting 131I Uptake and Mortality in Papillary Thyroid Cancer Patients with Lung Metastases. Cell Physiol Biochem. 2016; 40(6):1377-1390.

  64. Zhang XY, Song HJ, Qiu ZL, Shen CT, Chen XY, Sun ZK, Wei WJ, Zhang GQ, Luo QY. Pulmonary metastases in children and adolescents with papillary thyroid cancer in China: prognostic factors and outcomes from treatment with 131I. Endocrine. 2018. doi: 10.1007/s12020-018-1678-1.

  65. Shen CT, Zhang XY, Qiu ZL, Sun ZK, Wei WJ, Song HJ, Luo QY. Thyroid autoimmune antibodies in patients with papillary thyroid carcinoma: a double-edged sword? Endocrine. 2017; 58(1):176-183.

  66. Shen CT, Zhang Y, Liu YM, Yin S, Zhang XY, Wei WJ, Sun ZK, Song HJ, Qiu ZL, Wang CR, Luo QY. A distinct serum metabolic signature of distant metastatic papillary thyroid carcinoma. Clin Endocrinol (Oxf). 2017; 87(6):844-852.

  67. Shen CT, Qiu ZL, Song HJ, Wei WJ, Luo QY. miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(-) symporter in thyroid cancer by regulating MAPK signaling pathway. J Exp Clin Cancer Res. 2016; 35 (1):101.

  68. Song HJ, Qiu ZL, Shen CT, Wei WJ, Luo QY. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. Eur J Endocrinol. 2015; 173 (3):399-408.

  69. Qiu ZL, Shen CT, Song HJ, Wei WJ, Luo QY. Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study. Nucl Med Biol. 2015; 42 (5):499-504.

Wei Research Group @ Renji Hospital, School of Medicine, Shanghai Jiao Tong University

bottom of page